Literature DB >> 24199960

Markers of cholesterol transport are associated with amyloid deposition in the brain.

Timothy M Hughes1, Oscar L Lopez2, Rhobert W Evans3, M Ilyas Kamboh4, Jeff D Williamson5, William E Klunk6, Chester A Mathis7, Julie C Price7, Ann D Cohen6, Beth E Snitz2, Steven T Dekosky8, Lewis H Kuller5.   

Abstract

Cholesterol is implicated in the development of late-onset Alzheimer's disease (AD). We sought to determine the associations between beta amyloid (Aβ) plaque deposition in vivo using Pittsburgh compound B (PiB) and several indices of cholesterol homeostasis (i.e., total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, apolipoprotein E (ApoE), clusterin, oxysterol metabolites of cholesterol, and previously reported genes associated with late-onset AD) in 175 nondemented elderly subjects. High Aβ deposition was associated significantly with a lower Mini-Mental State Examination score (<27 points, p = 0.04), high systolic blood pressure (p = 0.04), carrying the apolipoprotein E epsilon 4 allele (p < 0.01), and lower plasma ApoE levels (p = 0.02), and variation in the ABCA7 (p = 0.02) and EPHA1 genes (p = 0.02). Cholesterol measures were not related to Aβ deposition in this cohort of nondemented elderly adults. However, plasma and genetic factors relating to cholesterol transport were associated with Aβ deposition in the brain. A better understanding of cholesterol transport mechanisms may lead to the design of potential targets for the prevention of Aβ deposition in the brain.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Cholesterol; Genes; Imaging; Lipids; Mild cognitive impairment; Oldest old

Mesh:

Substances:

Year:  2013        PMID: 24199960      PMCID: PMC3896052          DOI: 10.1016/j.neurobiolaging.2013.09.040

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  31 in total

1.  Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.

Authors:  D Lütjohann; A Papassotiropoulos; I Björkhem; S Locatelli; M Bagli; R D Oehring; U Schlegel; F Jessen; M L Rao; K von Bergmann; R Heun
Journal:  J Lipid Res       Date:  2000-02       Impact factor: 5.922

2.  Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases.

Authors:  L Bretillon; A Sidén; L O Wahlund; D Lütjohann; L Minthon; M Crisby; J Hillert; C G Groth; U Diczfalusy; I Björkhem
Journal:  Neurosci Lett       Date:  2000-10-27       Impact factor: 3.046

Review 3.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain.

Authors:  I Björkhem
Journal:  J Intern Med       Date:  2006-12       Impact factor: 8.989

4.  The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia.

Authors:  Steven T DeKosky; Annette Fitzpatrick; Diane G Ives; Judith Saxton; Jeff Williamson; Oscar L Lopez; Gregory Burke; Linda Fried; Lewis H Kuller; John Robbins; Russell Tracy; Nancy Woolard; Leslie Dunn; Richard Kronmal; Richard Nahin; Curt Furberg
Journal:  Contemp Clin Trials       Date:  2006-04-19       Impact factor: 2.226

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  The Mini-Mental State Examination.

Authors:  M F Folstein; L N Robins; J E Helzer
Journal:  Arch Gen Psychiatry       Date:  1983-07

7.  Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Authors:  Julie C Price; William E Klunk; Brian J Lopresti; Xueling Lu; Jessica A Hoge; Scott K Ziolko; Daniel P Holt; Carolyn C Meltzer; Steven T DeKosky; Chester A Mathis
Journal:  J Cereb Blood Flow Metab       Date:  2005-11       Impact factor: 6.200

Review 8.  Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.

Authors:  B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

9.  In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Authors:  Chester A Mathis; Lewis H Kuller; William E Klunk; Beth E Snitz; Julie C Price; Lisa A Weissfeld; Bedda L Rosario; Brian J Lopresti; Judith A Saxton; Howard J Aizenstein; Eric M McDade; M Ilyas Kamboh; Steven T DeKosky; Oscar L Lopez
Journal:  Ann Neurol       Date:  2013-04-17       Impact factor: 10.422

10.  Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry.

Authors:  S Dzeletovic; O Breuer; E Lund; U Diczfalusy
Journal:  Anal Biochem       Date:  1995-02-10       Impact factor: 3.365

View more
  29 in total

Review 1.  ATP-binding cassette transporter A1: from metabolism to neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Neurobiol Dis       Date:  2014-05-17       Impact factor: 5.996

Review 2.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

3.  Neuroimaging genetic risk for Alzheimer's disease in preclinical individuals: From candidate genes to polygenic approaches.

Authors:  Theresa M Harrison; Susan Y Bookheimer
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-01-01

4.  Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study).

Authors:  Amanda N Szabo-Reed; Eric Vidoni; Ellen F Binder; Jeffrey Burns; C Munro Cullum; William P Gahan; Aditi Gupta; Linda S Hynan; Diana R Kerwin; Heidi Rossetti; Ann M Stowe; Wanpen Vongpatanasin; David C Zhu; Rong Zhang; Jeffrey N Keller
Journal:  Contemp Clin Trials       Date:  2019-03-01       Impact factor: 2.226

5.  Statins and brain integrity in older adults: secondary analysis of the Health ABC study.

Authors:  Neelesh K Nadkarni; Subashan Perera; Joseph T Hanlon; Oscar Lopez; Anne B Newman; Howard Aizenstein; Marshall Elam; Tamara B Harris; Stephen Kritchevsky; Kristine Yaffe; Caterina Rosano
Journal:  Alzheimers Dement       Date:  2015-01-12       Impact factor: 21.566

Review 6.  ABCA7 in Alzheimer's Disease.

Authors:  Qing-Fei Zhao; Jin-Tai Yu; Meng-Shan Tan; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-31       Impact factor: 5.590

7.  Association between clusterin concentration and dementia: a systematic review and meta-analysis.

Authors:  Caiping Yang; Hai Wang; Chaojiu Li; Huiyan Niu; Shunkui Luo; Xingzhi Guo
Journal:  Metab Brain Dis       Date:  2018-10-05       Impact factor: 3.584

8.  Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis.

Authors:  Liana G Apostolova; Shannon L Risacher; Tugce Duran; Eddie C Stage; Naira Goukasian; John D West; Triet M Do; Jonathan Grotts; Holly Wilhalme; Kwangsik Nho; Meredith Phillips; David Elashoff; Andrew J Saykin
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

9.  Metabolic Syndrome and Amyloid Accumulation in the Aging Brain.

Authors:  Gabriela Gomez; Lori L Beason-Held; Murat Bilgel; Yang An; Dean F Wong; Stephanie Studenski; Luigi Ferrucci; Susan M Resnick
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 10.  The Potential of 'Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer's Disease in African Americans.

Authors:  Kaitlyn E Stepler; Renã A S Robinson
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.